What FDA, EU MDR and surgical robotics teach us about responsible scale
AI, software as a medical device and surgical robotics only create clinical value when safety, evidence and accountability are built in from the start.
This page summarises the original article. Read the complete piece on LinkedIn.
Artificial intelligence, software as a medical device (SaMD) and surgical robotics are changing how care is delivered, from image-guided procedures to clinical decision support. Technical novelty, however, does not create clinical value on its own.
The argument in brief
- Sustainable adoption depends on whether safety, evidence, accountability and regulatory readiness are designed into the product from the beginning.
- “Compliance by design” means embedding regulatory requirements, risk management, clinical validation and ethical governance across the whole device lifecycle.
- Treating compliance as a final checkpoint before market entry is slower and riskier than treating it as a design input.
Why it matters for clients
The piece draws on Dr. Allama’s compliance work with surgical and humanoid robotics projects in the GCC. For MedTech and digital-health teams, the practical message is to plan evidence and documentation once, for both US and European pathways, rather than retrofitting them late.